Interestingly, in melanoma patients treated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor tremelimumab, an association was observed between immune-related toxicity and whole blood RNA expression after 30 days of treatment [21]. The gene discussed is CTLA4; the disease is melanoma.